Insecticides (India) Ltd. Share Price

PIIndustriesLtd has received registration for Pioxaniliprole

Industries Limited has received registration for Pioxaniliproleunder Section 9(3) of the Insecticides Act, 1968. The company describes it as India’s first discovered insecticide, and the registration covers the TIM and FIM categories. The development is relevant because this is not simply another product launch. Registration is an important regulatory step before commercialisation, and Pioxaniliprole gives PI Industries an opportunity to build a domestic product around an active ingredient discovered in India. The registration follows the minutes of the 476th Registration Committee meeting held on September 10, 2026, which were published by the Ministry of Agriculture & Farmers Welfare on September 21. ([The Economic Times][1]) My view: the regulatory approval improves the company's product pipeline, but investors should separate registration from actual earnings. The next question is commercial execution. Pricing, formulation launches, farmer adoption, distribution reach and eventual volumes will determine how meaningful the product becomes for revenue and margins. For agrochemical companies, product differentiation can also matter because new molecules may offer better positioning than heavily commoditised products. However, the commercial opportunity will depend on the crops and pest applications covered, competitive products and the company's ability to scale distribution. From a technical perspective, I would avoid treating the registration itself as a guaranteed price catalyst. The September 22 high and the recent consolidation range should be used as reference levels. A volume-backed breakout would provide stronger confirmation, while failure to sustain the news-led move would indicate that investors want evidence of commercial traction. Disclosure: I have no holding or position in PI Industries Limited at the time of writing PI Industries Limited has received registration for Pioxaniliprole

See More

PI Industries Ltd. is an integrated agrisciences company based in India. Founded in 1946, it operates via a unique

PI Industries Ltd. is an integrated agrisciences company based in India. Founded in 1946, it operates via a unique business model combining domestic crop protection distribution with global Custom Synthesis and Manufacturing (CSM) ***** OverviewHeadquarters: Gurugram, ***** Office: Udaipur, ***** Mayank Singhal serves as Vice Chairman and Managing ***** Listings: Traded publicly on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).Business Model & SegmentsCustom Synthesis & Manufacturing (CSM): Partners with global life science innovators. Handles process research, scaling up, and large-scale manufacturing for active ingredients and chemical ***** Agri-Inputs: Develops, markets, and sells crop protection products. Includes insecticides, herbicides, and biostimulants for crops like rice, cotton, and ***** ProductsInsecticides: Osheen, Dorito, and ***** Biovita and ***** Pipeline: Launching Pioxaniliprole, India's first indigenously invented and patented insecticide for eco-friendly pest management.R&D and Manufacturing ScaleInfrastructure: Operates automated multipurpose plants across major manufacturing sites in Panoli and Jambusar, ***** Focus: Houses an R&D facility in Udaipur employing hundreds of scientists focused on advanced chemical synthesis and green chemistry.

See More

GODREJAGRO Soars Nearly 10% on Product Buzz; Eases From High

surged as much as 9.93% intraday on Thursday, 12 Feb 2026, touching ₹650 — its highest level since 6 November 2025. The rally was largely sentiment-driven, supported by the launch of its new insecticide “Takai” for rice crops. The product announcement boosted investor confidence and triggered strong buying interest during the session. Although the stock cooled off from its day’s high, it remained firmly in the green, closing at ₹630, up 6.54%. Market participants will now track whether the stock sustains momentum above key resistance levels or witnesses profit booking near higher zones. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

See More

HIL Ltd: Navigating Diversification in Chemicals and Agro Solutions

📌 A Legacy Evolving Beyond Insecticides HIL Ltd (formerly Hindustan Insecticides Ltd) has transformed from a traditional insecticide maker into a diversified chemical player. Its portfolio spans industrial chemicals, agrochemicals, paints & coatings, and specialty products. ⚙️ Core Business Verticals ✅ Industrial Chemicals & Chlor-Alkali: Produces caustic soda, hydrochloric acid, and derivatives essential for textiles, detergents, paper, pharma, and construction. ✅ Agrochemicals: Focuses on technicals and formulations, serving niche farmer needs amid stiff competition and regulatory challenges. ✅ Consumer Products: Markets pesticides like chlordane powder, enhancing brand presence though contributing modestly to revenue. 📈 Market Dynamics & Margin Sensitivity - Industrial chemicals operate in volatile commodity markets where pricing, supply-demand, and energy costs drive revenue swings. - Margins fluctuate with raw material and energy price shifts, reflecting the cyclical nature of bulk chemical businesses. 🌾 Agro Segment Challenges - Growth is constrained by crop cycles, regulatory approvals, and pricing pressures from multinational formulators. - Revenue contribution varies, mirroring agricultural seasonality and input cost dynamics. 💰 Financial Performance Snapshot - Earnings tend to be cyclical: strong global demand and firm commodity prices boost volumes and margins. - Conversely, downturns compress margins and slow revenue growth, leading to uneven year-on-year trends. - Working capital remains substantial due to inventory needs aligned with demand forecasts. Are you tracking how HIL manages these cyclical swings or its move into specialty chemicals? Share your thoughts!

See More

Struggles as Revlimid Windfall Fades

’s shares have dropped 38% from their 52-week high as investors grow wary of its volatile, high-risk business model. The company’s reliance on complex generics and Para-IV patent challenges has delivered blockbuster gains in the past, but earnings are now under pressure as its Revlimid opportunity fades and competition intensifies. - High-Risk Para-IV Strategy Natco specializes in niche, complex drugs—cancer treatments, injectables, peptides—and challenges patents through Para-IV filings. This strategy allows early generic launches but creates earnings volatility, as exclusivity periods are short-lived. - Revlimid Windfall Nears End Revlimid, Natco’s biggest success, doubled revenues and lifted margins from 14% in FY22 to nearly 50% in FY25. However, restricted volumes under its settlement with BMS/Celgene have eased, allowing rivals in. Natco confirmed most Revlimid earnings were realized in H1FY26, with steep declines expected thereafter. - Sharp Earnings Volatility Revenue fell from ₹1,371 crore in Q2FY25 to ₹475 crore in Q3FY25, with margins collapsing from 59% to 8%. For H2FY26, Natco guides quarterly revenue of ₹750–800 crore and PAT of ₹135–150 crore—a sequential decline of ~41% and ~71%. - Dependence on Few Products Analysts caution that near-term growth hinges on Revlimid, CTPR (insecticide Chlorantraniliprole), and upcoming launches like Risdiplam and Semaglutide. Both new drugs face regulatory and legal uncertainties, adding to earnings risk. Valuation remains stretched at 25x FY27 P/E. - Pipeline and Diversification Efforts Natco is advancing several complex, high-entry-barrier drugs and expanding geographically via the Adcock Ingram buyout in South Africa. While this reduces dependence on the US, meaningful contributions will take time. The market remains unconvinced until new products replace the fading Revlimid windfall.

See More